We contact authors of published studies to request additional information, when needed, in order to accurately include their study in our evidence synthesis.
Authors who have provided aggregated data of their studies are listed below.
Absalon-Aguilar A, J Gen Intern Med, 2021 - Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID) - NCT04367168
Ader F, Lancet Infect Dis, 2022 - Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial - NCT04315948, EudraCT2020-000936-23
Ahmed S, Int J Infect Dis, 2020 - A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Alemany A, Lancet Respir Med, 2022 - High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial - NCT04621123
Aman J, Lancet Respir Med, 2021 - Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial - NCT04794088
Babalola O E, medRxiv, 2021 - Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos - ISRCTN40302986
Balcells M, PLoS Med, 2021 - Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial - NCT04375098
Balykova L, Infektsionnye bolezn, 2020 - New possibilities for targeted antiviral therapy for COVID-19. Results of a multi center clinical study of the efficacy and safety of using the drug Areplivir - NCT04542694
Bar KJ, J Clin Invest, 2021 - A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia - NCT04397757
Bauer A, Lancet, 2021 - Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - NCT04353596
Beigel JH, N Engl J Med, 2020 - Remdesivir for the Treatment of Covid-19: Final Report - NCT04280705
Beltran-Gonzalez J, medRxiv, 2021 - Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial - NCT04391127
Bikdeli B, Thromb Haemost, 2021 - Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Cl
Boosteels C, Research Square, 2021 - Early treatment with inhaled GM-CSF improves oxygenation and anti-viral immunity in COVID-19 induced lung injury – a randomized clinical trial - NCT04326920
Bruen C, ResearchSquare, 2022 - Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial - NCT04345614
Cadegiani F, medRxiv, 2021 - Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial - NCT04728802
Cao Y, J Allergy Clin Immunol, 2020 - Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial - ChiCTR-OPN-2000029580
Caricchio R, JAMA, 2021 - Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19 - NCT04362813; EudraCT 2020-001370-30
Chen CP, Plos one, 2020 - A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) - NCT04384380
Chen J, Journal of Zhejiang, 2020 - Preliminary study of hydroxychloroquine sulfate in treating common coronavirus disease (COVID-19) patients in 2019 - NCT04261517
Chen P, Clin Pharmacol Ther, 2021 - First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19 - NCT04411628
Chen P, N Engl J Med, 2020 - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 - NCT04427501
Chuah CH, Clin Infect Dis, 2021 - Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial - NCT04818320
Connors JM, JAMA, 2021 - Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial - NCT04498273
Corral-Gudino L, medRxiv, 2020 - GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia - EudraCT2020-001934-37
De Marchi T, medRxiv, 2020 - Effects of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) in patients with severe COVID-19 requiring intubation: a pragmatic randomized placebo-controlled trial - NCT04386694
Doi Y, Antimicrob Agents Ch, 2020 - A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 - jRCTs041190120
Duarte M, EClinicalMedicine, 2021 - Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial - NCT04355936
Duvignaud A, Clin Microbiol Infect, 2022 - Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE) - NCT04356495
El-Bendary - RETRACTED ARTICLE: Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study
Elgazzar A, Research Square, 2020 - Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic - NCT04668469
Ezer N, BMJ, 2021 - Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial - NCT04435795
Finberg RW, Open Forum Infect Dis, 2021 - US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19 - NCT04358549
Fowotade A, medRxiv, 2022 - Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 - NCT04459286
Gharebaghi N, BMC Infect Dis, 2020 - The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial - IRCT20200501047259N1
Grieco DL, JAMA, 2021 - Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure The HENIVOT Randomized Clinical Trial - NCT04502576
Hermine O, JAMA Intern Med, 2020 - Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia - NCT04331808
Hinks T, Lancet Respir Med, 2021 - A randomised clinical trial of azithromycin versus standard care in ambulatory COVID19 - the ATOMIC2 trial - NCT04381962
Holubar M, Clin Infect Dis, 2022 - Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019 (COVID-19): A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial - NCT04346628
Huang YQ, Front Pharmacol, 2020 - No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate
Hung IF-N, Lancet, 2020 - Triple combination of interferon beta-1b, lopinavir+ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - NCT04276688
Huygens S, medRxiv, 2022 - Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial - NL9436
Johansson PI, Am J Respir Crit Care Med, 2021 - Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial - NCT04420741
Karampitsakos T, medRxiv, 2022 - Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial - NCT05082714
Khan Chachar AZ, Int J Sci, 2020 - Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients - NCT04739410
Kharat A, Thorax, 2021 - Self-proning in COVID-19 patients on low-flow oxygen therapy. A cluster randomised controlled trial - SNCTP000003718
Kumar PN, Open Forum Infect Dis, 2021 - Safety and Efficacy of Tocilizumab 4 or 8Â mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial - NCT04363736
Kyriazopoulou E, medrxiv, 2021 - Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor - NCT04680949; EudraCT 2020-005828-11
Lacombe K, Vox Sang, 2022 - COVID-19 convalescent plasma for hospitalized COVID-19 patients not requiring assisted ventilation. A randomized controlled trial - NCT04345991
Lanzoni G, Stem Cells Transl Me, 2020 - Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial - NCT04355728
Les I, Front Med, 2022 - Methylprednisolone Pulses in Hospitalized COVID-19 Patients Without Respiratory Failure: A Randomized Controlled Trial - NCT04438980
Li L, Jama, 2020 - Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19; A Randomized Clinical Trial - ChiCTR2000029757
Libster R, N Engl J Med, 2021 - Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults - NCT04479163
Lopes MIF, RMD Open, 2021 - Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial - RBR-8jyhxh
Lopez-Medina E, JAMA, 2021 - Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 - NCT04405843
Lou Y, medRxiv, 2020 - Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial - ChiCTR2000029544
Lowe DM, medRxiv, 2022 - Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - NCT04499677
Mariette X, Lancet Rheumatol, 2021 (CORIMUNO-SARI-1) - Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial - NCT04324073
Mazeraud A, Lancet Respir Med, 2021 - Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial - NCT04350580
Mitja O, Clin Infect Dis, 2020 - Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial - NCT04304053
Montgomery H, Lancet Respir Med, 2022 - Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial - NCT04723394
Mukae H, medRxiv, 2022 a - A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part - jRCT2031210350
Mukae H, medRxiv, 2022 b - Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study - jRCT2031210350
Munch M, JAMA, 2021 - Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial - NCT04509973; CTRI/2020/10/028731
Najmeddin F, Am J Hypertens, 2021 - Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial - IRCT20151113025025N3
NCT04385199, Unpublished, 2022 - Convalescent Plasma for Patients With COVID-19 - NCT04385199
NCT04411680, Unpublished, 2022 - Study of Sargramostim in Patients With COVID-19 (iLeukPulm) - NCT04411680
Neuenschwander FC, medRxiv, 2022 - Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia - NCT04467840
O'Brien M, JAMA, 2022 - Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection - NCT04452318
O'Donnell M, medRxiv, 2021 - A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19 - NCT04359810
Odeyemi YE, Crit Care, 2022 - Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial - NCT03852537
Parikh D, medRxiv, 2021 - Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial - CTRI/2020/09/027903
Pott-Junior H, Toxicology Reports, 2021 - Use of ivermectin in the treatment of Covid-19: A pilot trial - NCT04431466
Purwati, Biochem Res Int, 2021 - A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild
Ranjbar K, BMC Infect Dis, 2021 - Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial - IRCT20200204046369N1
Ravichandran R, medRxiv, 2021 - Indomethacin Use for Mild & Moderate hospitalised Covid-19 patients: An open label randomized clinical trial - CTRI/2021/05/033544
Ravikirti R, J Pharm Pharm Sci, 2021 - Ivermectin as a potential treatment for mild to moderate COVID-19? A double blind randomized placebo-controlled trial - CTRI/2020/08/027225
Redondo-Calvo FJ, Eur J Clin Invest, 2022 - Aprotinin treatment against SARS-CoV-2: a randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19 - EudraCT 2020–002434–33
Ren Z, Adv Sci, 2020 - A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study - ChiCTR2000029853
Rocco PRM, Eur Respir J, 2020 - Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial - NCT04552483
Rosas IO, EClinicalMedicine, 2022 - Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia - NCT04320615
Sabico S, Nutrients, 2021 - Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial - SCTR20061006
Sakoulas G, Crit Care Expl, 2020 - Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection - NCT04411667
Salama C, N Engl J Med, 2020 - Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia - NCT04372186
Samsonov M, Unpublished, 2022 - Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) - NCT04380519
Sanchez-Conde M, SSRN, 2022 - Pembrolizumab in combination with tocilizumab in high-risk hospitalized COVID-19 patients (COPERNICO): A randomized proof-of-concept phase II study - NCT04335305
Sancho-Lopez A, Infec Dis Ther, 2021 - Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study) - EU-CTR 2020-002037-15
Sasson J, medRxiv, 2022 - Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial - NCT04920916
Sekine L, Eur Respir J, 2021 - Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial - NCT04547660
Shahbaznejad L, Clin Ther, 2021 - Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial - IRCT20111224008507N3
Sholzberg, M, BMJ, 2021 - Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial - NCT04362085; NCT04444
Siami Z, Int J Infect Dis, 2021 - Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial - IRCT20200504047298N3
Simonovich VA, N Engl J Med, 2020 - A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia - NCT04383535
Sivapalan P, Eur Respir J, 2021 - Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial - EudraCT 2020-001198-55
Skipper CP, Ann Intern Med, 2020 - Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 - NCT04308668
Somersan-Karakaya S, medRxiv, 2021 - REGEN-COV for the Treatment of Hospitalized Patients with Covid-19 - NCT04426695
Spyropoulos A, JAMA Intern Med, 2021 - Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. The HEP-COVID Randomized Clinical Trial - NCT04401293
Sullivan D, medrxiv, 2021 - Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma - NCT04373460
Tang W, BMJ, 2020 - Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial - ChiCTR2000029868
Temesgen Z, Lancet Respir Med, 2021 - Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial - NCT04351152
Udwadia Z, Int J Infect Dis, 2020 - Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial - CTRI/2020/05/025114
Vallejos J, BMC Infect Dis, 2021 - Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial - NCT04529525
Ventura-Carmenate Y, Transl Med Commun, 2021 - Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020 - NCT04473170
Vlaar APJ, Lancet Rheumatol, 2020 - Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial - NCT04333420
Wang Y, Lancet, 2020 - Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - NCT04257656
Yueping L, CellPress, 2020 - The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI) - NCT04252885
Zheng F, Int J Infect Dis, 2020 - A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19 - ChiCTR2000029496
Altay O, Adv Sci, 2021 - Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 - NCT04573153
Araimo F , J Med Virol, 2020 - Ozone as adjuvant support in the treatment of COVID?19:A preliminary report of probiozovid trial - NCT04366089
Babalola OE, QJM, 2021 - Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos - ISRCTN40302986
Bajpai M, An Acad Bras Cienc, 2022 - Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients - NCT04346446
Balcells M, PLoS Med, 2021 - Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial - NCT04375098
Beigel JH, N Engl J Med, 2020 - Remdesivir for the Treatment of Covid-19 — Final Report - NCT04280705
Beltran-Gonzalez J, medRxiv, 2021 - Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial - NCT04391127
Blum VF, EClinicalMedicine, 2021 - Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial - NCT04348409
Borba MGS, JAMA Netw Open, 2020 - Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) InfectionA Randomized Clinical Trial - NCT04323527
Cavalcanti AB, N Engl J Med, 2020 - Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 - NCT04322123
Chaccour C, EClinicalMedicine, 2021 - The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial - NCT04390022
Chen CP, Plos one, 2020 - A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) - NCT04384380
Chen P, N Engl J Med, 2020 - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 - NCT04427501
Chowdhury ATMM, EJMO, 2021 - A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients - NCT04434144
Corral-Gudino L, medRxiv, 2020 - GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia - EUCTR2020-001934-37-ES
Davoudi-Monfared E, Antimicrob Agents Ch, 2020 - A Randomized Clinical Trial of the Efficacy and Safety of Interferon ?-1a in Treatment of Severe COVID-19 - IRCT20100228003449N28
Fragoso-Saavedra S, medRxiv, 2021 - Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial - NCT04343963
Garcia de Alencar JC, CID, 2020 - Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19) - RBR-8969zg
Gharbharan A, Nat Commun, 2021 - Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection - NCT04342182
Jagannathan P, Nature, 2021 - Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial - NCT04331899
Johnston C, EClinicalMedicine, 2021 - Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial - NCT04354428
Khamis F, Int J Infect Dis, 2020 - Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia - NCT04385095
Khan Chachar AZ, Int J Sci, 2020 - Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients - NCT04739410
Lenze E, JAMA, 2020 - Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 - A Randomized Clinical Trial - NCT04342663
Lescure FX, Lancet Respir Med, 2021 - Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial - NCT04327388
Libster R, N Engl J Med, 2021 - Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults - NCT04479163
Lopez-Medina E, JAMA, 2021 - Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Tria - NCT04405843
Lyngbakken MN, Nature, 2020 - A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics - NCT04316377
Mahmud R, J Int Med Res, 2021 - Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial - NCT04523831
Marconi V, Lancet Respir Med, 2021 - Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - NCT04421027
Mariette X, Lancet Respir Med, 2021 - Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial - NCT04341584
Mehboob R, medRxiv, 2020 - Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach - NCT04468646
Nourian A, Acta Biomed, 2020 - Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial - IRCT20100228003449N29
O Donnell M, J Clin Invest, 2021 - A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19 - NCT04359810
Omrani A, EClinicalMedicine, 2020 - Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 - NCT04349592
Rahmani H, Int Immunopharmacol, 2020 - Interferon ?-1b in treatment of severe COVID-19: A randomized clinical trial - IRCT20100228003449N27
Ravikirti R, J Pharm Pharm Sci, 2021 - Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India - CTRI/2020/08/027225
Rea-Neto A, Scientific Reports, 2021 - An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients - NCT04420247
Roozbeh F, J Antimicrob Chemoth, 2020 - Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial - IRCT20200403046926N1
Salama C, N Engl J Med, 2020 - Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia - NCT04372186
Salehzadeh F, Research Square, 2020 - The Impact of Colchicine on The COVID-19 Patients; A Clinical Trial Study - IRCT20200418047126N1
Salvarani C, JAMA , 2020 - Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia - NCT04346355
Self W, JAMA, 2020 - Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 - A Randomized Clinical Trial - NCT04332991
Silva M, medRxiv, 2021 - Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study - NCT04463264
Simonovich VA, N Engl J Med, 2020 - A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia - NCT04383535
Tardif JC, Lancet Respir Med, 2021 - Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial - NCT04322682
Tomazini BM, JAMA, 2020 - Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial - NCT04327401
Yakoot M, medRxiv, 2022 - Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study - DRKS00022203